ZYDUSLIFE — Zydus Lifesciences Balance Sheet
0.000.00%
- IN₹993.81bn
- IN₹971.95bn
- IN₹232.42bn
- 92
- 30
- 97
- 88
Annual balance sheet for Zydus Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,816 | 40,818 | 11,876 | 13,530 | 78,039 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 38,518 | 39,395 | 50,816 | 60,473 | 49,435 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 87,160 | 122,614 | 100,164 | 115,014 | 170,461 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 63,332 | 64,226 | 68,267 | 69,148 | 73,599 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 238,847 | 277,954 | 257,564 | 292,808 | 372,017 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 78,613 | 78,394 | 55,307 | 53,419 | 90,416 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 108,924 | 107,958 | 82,406 | 94,513 | 132,486 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 129,923 | 169,996 | 175,158 | 198,295 | 239,531 |
| Total Liabilities & Shareholders' Equity | 238,847 | 277,954 | 257,564 | 292,808 | 372,017 |
| Total Common Shares Outstanding |